According to a Reuters article, Impax Laboratories Inc. agreed to acquire a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd. and Allergan Plc for about $586 million.
The deal is said to be part of the divestiture process mandated by the FTC in relation to Teva's acquisition of Allergan's generics business for $40.5 billion, the story said.
Impax said it will also take back from Teva rights to a generic version of Concerta, an ADHD drug made by Johnson & Johnson.
Read the complete article
